Hemostasis Notes

Vascular Pathology

Cardiovascular diseases are a leading cause of death. The cardiovascular system includes the heart, blood, and vessels; alterations in one component affect the others. Key cells involved are white blood cells, RBCs, and platelets.

Distinct Vessels, Distinct Pathologies

• Arteries and veins: Three layers (intima, media, adventitia).

• Capillaries: No media, allow gas exchange.

• Post-capillary venules: Site of vascular leakage and leukocyte extravasation.

Different vessels are prone to specific diseases (e.g., atherosclerosis in arteries, disseminated intravascular coagulopathy in small vessels). Endothelial cells maintain a non-reactive state but become pro-adhesive and pro-thrombogenic upon activation by stimuli like cytokines, bacteria, toxins, shear stress, and pressure.

Hemostasis

Hemostasis is the overall process of stopping bleeding, while coagulation is a fraction of it. It involves primary and secondary hemostasis. The clot consists of entrapped RBCs, platelets, leukocytes, and fibrin.

Endothelial cells actively prevent clot formation by maintaining a non-hemostatic state. A clot is physiological, whereas a thrombus is pathological, forming without a physiological injury (e.g., due to atherosclerosis).

Thrombi in arteries often form at atherosclerotic plaques, while venous thrombosis can occur due to hypercoagulable states.

Steps of Hemostatic Process

1. Arteriolar vasoconstriction.

2. Primary hemostasis.

3. Secondary hemostasis.

4. Clot stabilization and resorption.

Primary hemostasis involves platelet aggregation. Platelets adhere to exposed collagen via von Willebrand factor (vWF). Activated platelets release pro-coagulation factors (ADP, thromboxane A2, vWF). Secondary hemostasis involves the coagulation cascade, triggered by tissue factor, leading to thrombin activation and fibrin formation. Fibrinogen, a coagulation factor, also serves as an inflammatory marker.

Steps of Hemostasis in Detail

• Vascular phase: Vasoconstriction mediated by neurogenic reflexes and endothelin.

• Platelet phase: Platelet activation, aggregation, and degranulation; vWF binds to platelets promoting adhesion, and release of TXA_2 and ADP.

• Coagulation phase: Activation of coagulation cascade.

• Clot retraction.

• Clot destruction: Dissolution of clot.

Primary Hemostasis: Platelet Aggregation

Disrupted endothelium exposes collagen, which binds vWF. vWF promotes platelet adhesion and activation, releasing TXA_2 and ADP.

Platelets

Anucleated cell fragments (150-450 x 10^3/mm^3). They contain α-granules (P-selectin, vWF, fibrinogen) and dense granules (ADP, thromboxane A2, serotonin). Activated platelets change shape, increasing surface area and expressing GpIIb/IIIa for fibrinogen binding. Platelets also have receptors (GPIb) for vWF.

Secondary Hemostasis: Coagulation Cascade

Occurs alongside platelet aggregation. Tissue factor exposure activates Factor VII, initiating the coagulation cascade, culminating in thrombin activation. Thrombin converts fibrinogen to fibrin, consolidating the platelet plug.

Coagulation Cascade

Two pathways:

• Intrinsic: Occurs within blood (contact with negatively charged substances).

• Extrinsic: Occurs at the site of vascular wall trauma (contact with tissue factor).

Both converge on activation of pro-thrombin to thrombin. Thrombin activates fibrinogen to fibrin, stabilized by Factor XIII. Fragments from fibrin indicate fibrinolysis.

Each step involves an enzyme, a substrate, and a cofactor. Calcium and Vitamin K are essential; Vitamin K adds carboxyl groups to Factors II, VII, IX, and X, enabling Calcium chelation. Vitamin K is antagonized by coumarins (anticoagulant drugs).

Anticoagulants inhibit coagulation, while anti-aggregates (e.g., aspirin) block platelet aggregation by blocking the COX pathway. Thrombin mediates multiple functions: fibrin formation, platelet activation, endothelial cell/leukocyte activation, and anticoagulant activity on normal endothelium. Intact endothelial cells expose thrombomodulin, which binds thrombin and activates protein C, inhibiting coagulation.

Regulation of Coagulation

Mechanisms to prevent unwanted coagulation include dilution of coagulation factors, fibrinolytic cascade, and inhibitor signals from intact endothelial cells.

Normal endothelium:

• Physical barrier.

• Anti-aggregant (NO and PGI_2).

• Anticoagulant (thrombomodulin).

• Pro-fibrinolytic (t-PA).

Fibrinolysis

Plasmin, generated from plasminogen, cleaves fibrin. Key activators of plasminogen: Factor XII and t-PA; t-PA is most active when bound to fibrin.

…………………..

questions

Thank you for your answers! Let's go through each one together: I’ll give feedback on your response, correct anything inaccurate, and then provide the model answer for each question based on your PDF.

⚠ 2. What is the main functional difference between a clot and a thrombus?

Your answer: "A thrombus is formed at the level of the vascular wall but the clot can be free and move with blood and cause disruption in the cardiovascular system and lead to stroke."
🟡 Partially correct. But there is confusion between a clot and an embolus.

Correction:
A clot is a physiological process that happens in response to injury (to stop bleeding).
A thrombus is a pathological clot that forms without a physiological trigger (e.g., due to atherosclerosis, hypercoagulability) and can block vessels.

An embolus is a free-floating fragment (often from a thrombus) that can travel and cause stroke or embolism.

Model answer:

❌ 3. Why do atherosclerotic plaques typically cause arterial thrombosis but not venous thrombosis?

Your answer: "I dunno"
Correct answer:

✅ 4. List the four main steps of the hemostatic process. Which are the most clinically significant?

Your answer: "The 4 important steps are the arteriolar vasoconstriction, primary and secondary hemostasis and clot stabilization and resolution. The most clinically significant is secondary, where coagulation factors are involved."
✔ Correct and well explained.
Model answer:

1. Arteriolar vasoconstriction

2. Primary hemostasis (platelet plug)

3. Secondary hemostasis (coagulation cascade)

4. Clot stabilization and reabsorption

🟡 5. How do endothelial cells normally prevent clot formation?

Your answer: "They express a protein or receptor... that activates protein C which binds protein S... also thrombin has an anticoagulant role on intact endothelium."
🟢 Good job, but needs clarity and completeness.

Model answer:

• Releasing NO and prostacyclin (PGI2) → inhibit platelet aggregation

• Expressing thrombomodulin, which binds thrombin → activates protein C, which with protein S, inhibits coagulation (factors V and VIII)

• Producing tPA → activates fibrinolysis

• Acting as a physical barrier that prevents platelet contact with subendothelial factors like collagen and vWF

✅ 6. What is the role of collagen and tissue factor in hemostasis initiation?

Your answer: "Collagen binds vWF → platelets; tissue factor → extrinsic coagulation cascade"
✔ Correct!
Model answer:

⚠ 7. What is Virchow’s Triad, and which element is most significant in venous thrombosis?

Your answer: "I don’t know the first part... but in venous thrombosis, due to lower blood flow, more RBCs are trapped (red thrombus)."
🟡 Partial credit. You identified the red thrombus part correctly.

Model answer:

1. Stasis of blood flow

2. Endothelial injury

3. Hypercoagulability

.

🧬 What is t-PA?

t-PA stands for Tissue Plasminogen Activator.
It’s a serine protease enzyme released by endothelial cells, especially at the site of vascular injury.

🔹 Function of t-PA:

t-PA converts plasminogen (an inactive zymogen in plasma) into plasmin, the active enzyme that breaks down fibrin.

🔸 Step-by-step:

1. Plasminogen is incorporated into the clot during formation.

2. t-PA, when bound to fibrin, activates plasminogen → plasmin.

3. Plasmin digests the fibrin mesh → producing fibrin degradation products (FDPs).

4. This results in clot dissolution (fibrinolysis).

🔹 Key Properties:

• t-PA is most active when bound to fibrin, which means it targets clots specifically — this is why it's used clinically in thrombolytic therapy.

• It is naturally regulated by inhibitors like PAI-1 (plasminogen activator inhibitor-1) to prevent excessive clot breakdown.

💊 Clinical Use of t-PA:

• Recombinant t-PA (alteplase) is used as a thrombolytic drug in:

  • Acute ischemic stroke (within 4.5 hours)

  • Myocardial infarction

  • Pulmonary embolism

🧠 Summary Sentence:

……………………..